Efficacy and Safety of Coenzyme Q10 in Pediatric Hemodialysis Patients
- Conditions
- Hemodialysis
- Interventions
- Dietary Supplement: Coenzyme Q10Other: Placebo
- Registration Number
- NCT05170893
- Lead Sponsor
- Ain Shams University
- Brief Summary
All chronic kidney disease patients, whether on regular hemodialysis or not, are at high risk of cardiovascular diseases. This is mainly due to increased oxidative stress, reduced antioxidants and generalized inflammation. Coenzyme Q10 is a vitamin-like antioxidant synthesized in almost all body cells, and it is also available in many dietary sources. It was observed that chronic kidney disease patients have low plasma levels of Coenzyme Q10. Clinical benefits of Coenzyme Q10 supplementation have been documented for various cardiovascular and neurodegenerative disorders. The investigators believe that Coenzyme Q10 supplementation may have potential benefits in pediatric patients receiving hemodialysis; mainly due to its antioxidant activity and anti-inflammatory effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
- Male or female patients with ages between 2 to 18 years old.
- Undergoing regular hemodialysis for at least 6 months.
- Patients who weigh less than 10 kg.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intervention group Coenzyme Q10 Oral Coenzyme Q10 capsules daily for 12 weeks. Control group Placebo Oral capsules similar to the intervention daily for 12 weeks.
- Primary Outcome Measures
Name Time Method Change in Malondialdehyde (MDA) 12 weeks marker of oxidative stress
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
El-Demerdash Children's Hospital
🇪🇬Cairo, Egypt